Af­ter six years in the role, BeiGene’s hema­tol­ogy CMO has an­nounced her up­com­ing de­par­ture.

The biotech kept it short in an 8-K filed yes­ter­day, but here’s what we know: Jane Huang, fea­tured in our Top 20 Women in Bio­phar­ma spe­cial re­port just three months ago, ten­dered her res­ig­na­tion and gave 30 days no­tice on Wednes­day — and she will be no longer work­ing as an em­ploy­ee af­ter April 3. No rea­son was giv­en for her de­par­ture, and there has been no men­tion of who her re­place­ment will be.

Huang came to BeiGene in 2016 af­ter a short run at Ac­er­ta as their VP and head of clin­i­cal de­vel­op­ment. Be­fore Ac­er­ta, she had a 10-year stint at Genen­tech as a med­ical di­rec­tor.

Af­ter Huang of­fi­cial­ly re­signs on April 3rd, she will be a con­sul­tant for BeiGene for a few months un­til No­vem­ber 14. And that might come in handy with the churn­ing of R&D, the light of a his­toric bear mar­ket and what’s ex­pect­ed up ahead for its BTK in­hibitor Brukin­sa.

Back in Sep­tem­ber, the FDA ap­proved Brukin­sa for rare blood can­cer Walden­ström’s Macroglob­u­line­mia as BeiGene looked at rapid­ly ramp­ing up its US ex­pan­sion plans.

And af­ter show­ing Phase III da­ta in first-line chron­ic lym­pho­cyt­ic leukemia (CLL) or small lym­pho­cyt­ic leukemia (SLL) at ASH back in No­vem­ber, Huang told End­points News that while the com­pa­ny isn’t say­ing when it ex­pects to file for reg­u­la­to­ry ap­provals, it’s work­ing to get Brukin­sa to pa­tients in “as many coun­tries as pos­si­ble.”

BeiGene an­nounced last week that Brukin­sa is now await­ing a PDU­FA date of Oct. 22 for both CLL and SLL in­di­ca­tions.

Huang’s de­par­ture is one of the newest de­vel­op­ments hap­pen­ing in many biotech C-suites — with some­what of a small biotech CEO ex­o­dus, in­clud­ing Till­man Gern­gross from Ada­gio, Gem­i­ni Ther­a­peu­tics’ CEO Ja­son Meyen­berg, and Deepa Prasad re­signed from trou­bled Alzheimer’s play­er vTv Ther­a­peu­tics.

Microcap biotech Seelos Therapeutics is halting enrollment of its study in spinocerebellar ataxia type 3 (also known as Machado-Joseph disease) because of “financial considerations,” and in order to focus on other studies, the company said today, adding that the pause would be temporary.

The study will continue with the patients who have already enrolled, and the data from them will be used to decide whether to continue enrolling others in the future.

Otonomy may be shutting down, but the lessons learned there will live on at another biotech working on new treatments for hearing loss.

San Francisco-based Spiral Therapeutics has bought certain assets related to three of Otonomy’s programs, ranging from data, patent rights, and know-how to inventory. That includes data around Otonomy’s twice-failed lead program, OTO-104 (Otividex), a sustained-exposure formulation of dexamethasone.

Paul McKenzie took over as CEO of Australian pharma giant CSL this month, following in the footsteps of long-time CSL vet Paul Perreault.

With an eye on mRNA, and quickly commercializing its new, $3.5 million-per-shot gene therapy for hemophilia B, McKenzie and chief medical officer Bill Mezzanotte answered some questions from Endpoints News this afternoon about where McKenzie is going to take the company and what advances may be coming to market from CSL’s pipeline. Below is a lightly edited transcript.

Boehringer Ingelheim reported human pharma sales of €18.5 billion on Wednesday, led by type 2 diabetes and heart failure drug Jardiance and pulmonary fibrosis med Ofev. Jardiance sales reached €5.8 billion, growing 39% year over year, while Ofev took in €3.2 billion, notching its own 20.6% annual jump.

However, Boehringer is also looking ahead with its pipeline, estimating “In the next seven years the company expects about 20 regulatory approvals in human pharma.”